Passage Bio's 2025 net loss narrows
Overview
Genetic medicines firm's net loss for 2025 was $45.5 mln, smaller than $64.8 mln loss in 2024
Company advancing upliFT-D study for frontotemporal dementia
Cash runway expected through Q1 2027
Outlook
Passage Bio expects interim safety data from upliFT-D study in 1H 2026
Company aims to declare Huntington's disease clinical candidate in 2H 2026
Passage Bio has cash runway through 1Q 2027
Result Drivers
CLINICAL PROGRESS - Passage Bio advanced its upliFT-D study by enrolling first FTD-GRN patients in Cohort 3 and treating first FTD-C9orf72 patient in Cohort 4
HUNTINGTON'S PROGRAM - Co advancing preclinical program for Huntington’s disease with clinical candidate selection expected in 2H 2026
Company press release: ID:nGNX2PqQgm
Key Details
Metric | Beat/Miss | Actual | Consensus Estimate |
FY Net Income |
| -$45.52 mln |
|
FY Income From Operations |
| -$49.30 mln |
|
Analyst Coverage
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 6 "strong buy" or "buy", no "hold" and no "sell" or "strong sell"
The average consensus recommendation for the biotechnology & medical research peer group is "buy"
Wall Street's median 12-month price target for Passage Bio Inc is $32.00, about 264.5% above its March 2 closing price of $8.78
For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.
Related Articles
Spot Silver Prices Volatile, Losses Narrow After 7% Plunge, Has Safe-Haven and Industrial Narrative Failed?
TradingKey - During the Asian trading session, spot silver's intraday decline widened to as much as 7%, reaching $83.05/oz, before subsequently narrowing. As of press time, silver was trading at $85.8/oz. Influenced by recent severe tensions in the Middle East and a complex, volatile international landscape, global commodities—particularly pure benzene, liquefied petroleum gas (LPG), ethylene glycol, styrene, and polypropylene—have experienced significant volatility.
Bitcoin Stuck in Range Struggle, Can US-Iran Conflict Help a Breakout?
As the US-Iran conflict continues to escalate, Bitcoin prices remain range-bound and are losing their war premium.
JPMorgan Warns Hormuz Blockade Risks Oil Shutdown in 25 Days, But How Will the US-Iran Conflict Shape Global Oil Prices?
TradingKey - Following the announcement on the night of February 28 banning all vessels from passing through the Strait of Hormuz, JPMorgan Chase issued a warning: if the Strait of Hormuz is completely blocked, the combined onshore and offshore storage capacity of Middle Eastern oil-producing nation
US-Iran Conflict Ignites, Global Arms Race Heats Up, Will Defense Stocks See a New Round of Gains?
TradingKey - On February 28 local time, the United States and Israel launched joint large-scale airstrikes against Iran, targeting its nuclear facilities, missile industry, and naval forces. This marks another sharp escalation in the conflict following the US military strikes on Iranian nuclear facilities in June last year. The military operation not only exacerbates already strained geopolitical tensions but has also sent shockwaves through global capital markets, which is expected to further boost defense stocks.
The Hyperliquid Phenomenon: HYPE Ecosystem’s Path to $250
Explore the Hyperliquid (HYPE) 2026 outlook as it evolves from a high-speed DEX into a powerful Layer 1 ecosystem. This analysis breaks down the $2.95 trillion trading volume, the impact of the HIP-4 prediction market launch, and the HYPE token's technical resilience at the $31.77 level amidst globa
